{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:28:30Z","timestamp":1780442910090,"version":"3.54.1"},"reference-count":32,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,11,27]]},"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Non-illicit alternatives to controlled drugs, known as novel psychoactive substances (NPS), have recently risen to prominence. They are readily available, with uncertain pharmacology and no widely available assay. Given that psychiatric patients are at risk of comorbid substance abuse, we hypothesised that NPS use would be present in the psychiatric population, and sought to determine its prevalence and investigate the characteristics of those who use these drugs with a retrospective review of discharge letters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>General adult inpatient wards of a psychiatric hospital in a Scottish city.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All adult inpatients (18\u201365) discharged from general psychiatric wards between 1 July 2014 and 31 December 2014. Of the 483 admissions identified, 46 were admissions for maintenance electroconvulsive therapy (ECT) and were excluded. Of the remaining 437 admissions, 49 discharge letters were unobtainable, leaving 388 admissions to analyse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measure<\/jats:title>\n                    <jats:p>The mention, or lack thereof, of NPS use in discharge letters was our planned primary outcome measure and was also the primary outcome measure we used in our analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NPS use was identified in 22.2% of admissions, contributing to psychiatric symptoms in 59.3%. In comparison to non-users, NPS users were younger (p&lt;0.01), male and more likely to have a forensic history ((p&lt;0.001) for both). The diagnosis of drug-induced psychosis was significantly more likely in NPS users (p&lt;0.001, OR 18.7, 95% CI 8.1 to 43.0) and the diagnosis of depression was significantly less likely (p&lt;0.005, OR 0.133, CI 0.031 to 0.558). Use of cannabis was significantly more likely in NPS users (p&lt;0.001, OR 4.2, CI 2.5 to 7.1), as was substitute opiate prescribing (p&lt;0.001, OR 3.7, CI 1.8 to 7.4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NPS use was prevalent among young, male psychiatric inpatients, in particular those with drug-induced psychosis and often occurred alongside illicit drug use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009430","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:35:10Z","timestamp":1462926910000},"page":"e009430","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Use of novel psychoactive substances by inpatients on general adult psychiatric wards"],"prefix":"10.1136","volume":"6","author":[{"given":"Jack L","family":"Stanley","sequence":"first","affiliation":[{"name":"Undergraduate\u20145th year, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V","family":"Mogford","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NHS Lothian, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NHS Lothian, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Lawrie","sequence":"additional","affiliation":[{"name":"University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,5,10]]},"reference":[{"key":"2025121601214768000_6.5.e009430.1","unstructured":"2012\/13 Scottish Crime and Justice Survey: Drug Use. 2014; Scottish Centre for Crime and Justice Research. University of Glasgow. http:\/\/www.gov.scot\/Resource\/0045\/00453923.pdf (accessed 19 Mar 2015)."},{"key":"2025121601214768000_6.5.e009430.2","unstructured":"ACMD (Advisory Council on the Misuse of Drugs), Consideration of the Novel Psychoactive Substances (\u2018legal highs\u2019) October 2011. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/119139\/acmdnps2011.pdf (accessed 18 Mar 2015)."},{"key":"2025121601214768000_6.5.e009430.3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.drugpo.2011.12.003","article-title":"Virtually a drug scare: mephedrone and the impact of the internet on drug news transmission","volume":"23","author":"Forsyth","year":"2012","journal-title":"Int J Drug Policy"},{"key":"2025121601214768000_6.5.e009430.4","unstructured":"United Nations Office on Drugs and Crime (UNODC). World Drug Report 2014. https:\/\/www.unodc.org\/documents\/wdr2014\/World_Drug_Report_2014_web.pdf (accessed 16 Mar 2015)."},{"key":"2025121601214768000_6.5.e009430.5","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2012: annual report on the state of the drugs problem in Europe . 2012. http:\/\/www.emcdda.europa.eu\/publications\/annual-report\/2012 (accessed 16 Mar 2015)."},{"key":"2025121601214768000_6.5.e009430.6","unstructured":"United Nations Office on Drugs and Crime (UNODC). The Challenge of New Psychoactive Substances. Global SMART Programme 2013. http:\/\/www.unodc.org\/documents\/scientific\/NPS_2013_SMART.pdf (accessed 15 Mar 2015)."},{"key":"2025121601214768000_6.5.e009430.7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/157488411796151129","article-title":"Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly","volume":"6","author":"Corazza","year":"2011","journal-title":"Curr Clin Pharmacol"},{"key":"2025121601214768000_6.5.e009430.8","unstructured":"Home Office. Psychoactive Substances Bill. https:\/\/www.gov.uk\/government\/collections\/psychoactive-substances-bill-2015 (accessed 17 Jun 2015)."},{"key":"2025121601214768000_6.5.e009430.9","doi-asserted-by":"publisher","DOI":"10.1002\/dta.155"},{"key":"2025121601214768000_6.5.e009430.10","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181f33411"},{"key":"2025121601214768000_6.5.e009430.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.01.012"},{"key":"2025121601214768000_6.5.e009430.12","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.645952"},{"key":"2025121601214768000_6.5.e009430.13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.drugpo.2014.10.010","article-title":"Mortality related to novel psychoactive substances in Scotland, 2012: an exploratory study","volume":"26","author":"McAuley","year":"2015","journal-title":"Int J Drug Policy"},{"key":"2025121601214768000_6.5.e009430.14","doi-asserted-by":"publisher","DOI":"10.1097\/00001504-199605000-00013"},{"key":"2025121601214768000_6.5.e009430.15","first-page":"815424","article-title":"Novel psychoactive substances in young adults with and without psychiatric comorbidities","volume":"2014","author":"Martinotti","year":"2014","journal-title":"Bio Med Res Int"},{"key":"2025121601214768000_6.5.e009430.16","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.86.7.973"},{"key":"2025121601214768000_6.5.e009430.17","doi-asserted-by":"publisher","DOI":"10.1176\/ps.46.3.248"},{"key":"2025121601214768000_6.5.e009430.18","first-page":"229","article-title":"Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Focus","volume":"5","author":"Brady","year":"2007","journal-title":"Am Psychiatr Publ"},{"key":"2025121601214768000_6.5.e009430.19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1192\/pb.bp.111.038315","article-title":"Prevalence study of head shop drug usage in mental health services","volume":"37","author":"Lally","year":"2013","journal-title":"Psychiatrist"},{"key":"2025121601214768000_6.5.e009430.20","unstructured":"Abdulrahim D , Bowden-Jones O ., on behalf of the NEPTUNE Expert Group. Guidance on the management of acute and chronic harms of club drugs and novel psychoactive substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE), 2015."},{"key":"2025121601214768000_6.5.e009430.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2012.06.005"},{"key":"2025121601214768000_6.5.e009430.22","unstructured":"CREW 2000. NPS at Crew Annual Report 2014\u20132015. 2015. https:\/\/1fec16444e7228ff2981-b6e25eb72df69608d37cf0f90c328ddf.ssl.cf3.rackcdn.com\/2015041020-20NPS20ANNUAL20REPORT20-20201520-20FINAL20-202.pdf (accessed 28 Apr 2015)."},{"key":"2025121601214768000_6.5.e009430.23","first-page":"673","article-title":"Sociopathy and drug use in a young psychiatric population","volume":"36","author":"Westermeyer","year":"1975","journal-title":"Dis Nerv Syst"},{"key":"2025121601214768000_6.5.e009430.24","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2011.00060"},{"key":"2025121601214768000_6.5.e009430.25","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2312"},{"key":"2025121601214768000_6.5.e009430.26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2174\/1874473711205040005","article-title":"Single chemical entity legal highs: assessing the risk for long term harm","volume":"5","author":"McNabb","year":"2012","journal-title":"Curr Drug Abuse Rev"},{"key":"2025121601214768000_6.5.e009430.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2010.09.014"},{"key":"2025121601214768000_6.5.e009430.28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00437.x"},{"key":"2025121601214768000_6.5.e009430.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03351.x"},{"key":"2025121601214768000_6.5.e009430.30","doi-asserted-by":"publisher","DOI":"10.1159\/000346678"},{"key":"2025121601214768000_6.5.e009430.31","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.2.110"},{"key":"2025121601214768000_6.5.e009430.32","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2300"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:21:58Z","timestamp":1765876918000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,10]]},"published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1136\/bmjopen-2015-009430"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009430","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}